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Background: The Vantera Clinical Analyzerwas developed to enable fully-automated, high-throughput nuclear
magnetic resonance (NMR) spectroscopy measurements in a clinical laboratory setting. NMR-measured low-
density lipoprotein particle number (LDL-P) has been shown tobemore strongly associatedwith cardiovascular dis-
ease outcomes than LDL cholesterol (LDL-C) in individuals forwhom these alternatemeasures of LDL are discordant.
Objective: The aimof this studywas to assess the analytical performance of the LDL-P assay on theVantera Clin-
ical Analyzer as per Clinical Laboratory Standards Institute (CLSI) guidelines.
Results: Sensitivity and linearity were established within the range of 300–3500 nmol/L. For serum pools con-
taining low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefﬁ-
cients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2282 nmol/L
and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only 2 exhibited
the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera
Clinical Analyzer and NMR Proﬁler, showed excellent correlation (R2 = 0.96).
Conclusions: The performance characteristics suggest that the LDL-P assay is suitable for routine testing in the
clinical laboratory on the Vantera Clinical Analyzer, the ﬁrst automated NMR platform that supports NMR-based
clinical assays.
© 2014 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).Introduction
Measurements of lipoprotein concentrations are widely used to as-
sess and manage cardiovascular disease (CVD) risk. Lipoproteins move
from the circulation into the arterywall in a gradient driven fashion. Fol-
lowing entry and retention in the artery wall, low-density lipoproteins
(LDL) are oxidized, taken up bymacrophages to form foam cells and ac-
celerate atherosclerosis [1]. Conversely, high-density lipoproteins
(HDL) demonstrate a variety of functions that antagonize atherosclero-
sis [2]. Traditional methods for estimating circulating concentrations of
LDL and HDL measure their cholesterol content (LDL-C and HDL-C).-P, Low density lipoprotein par-
erol; CLSI, Clinical Laboratory
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rticle number; CLIA, Clinical
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Sumner Boulevard, Raleigh,
Matyus).
iety of Clinical Chemists. PublisHowever, the cholesterol content of lipoprotein particles varies widely
among individuals and is often dependent on the metabolic state of
the patient [3,4]. As a result, discordance is frequently noted between
LDL-C levels and nuclear magnetic resonance (NMR) measurements
of LDL particle number (LDL-P) [5–8]. As a CVD risk management tool,
LDL-C values indicate which patients have lowered their risk to accept-
able levels (as inferred from their treatment goal having been reached)
and which have not (indicating a need for more aggressive treatment).
Several large clinical studies demonstrate the limitations of this strategy
in that, when alternate measures of LDL are discordant, LDL-P is more
strongly associated with incident CVD events than LDL-C [5,6,9–18].
Consequently, several expert panels now recommend consideration of
LDL-P levels to adjudicate and guide medical decision-making [19–21].
Proton NMR spectroscopy has been successfully applied to the mea-
surement of lipoprotein particles, providing both concentration and
average size information for very low density lipoprotein (VLDL), inter-
mediate density lipoprotein (IDL), LDL, and HDL particles from a single
serum or plasma sample [22]. This measurement is based on the proton
magnetic resonance signals from terminal methyl groups on lipids
within the core and shell of lipoprotein particles and the fact that the
amplitude of the methyl NMR signal is proportional to the concentra-
tion of the particles. In addition, lipoproteins have distinctmethyl signalhed by Elsevier Inc. This is an open access article under the CC BY license
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methyl signal envelope to be deconvoluted to provide the contributing
signal amplitudes of the different-size subclasses of VLDL, LDL, and HDL,
which in turn provide their particle concentrations [22].
NMR lipoprotein analysis has been commercially available for years
as a Laboratory Developed Test (LDT) provided by a central testing
facility, LipoScience, Raleigh, NC. The NMR LipoProﬁle® test, which was
cleared as an in vitro diagnostic (IVD) by the Food andDrug Administra-
tion (FDA) on the NMR Proﬁler (2008) and Vantera Clinical Analyzer
(2012), measures particle concentrations for all lipoprotein classes
(VLDL, LDL, HDL) and subclasses (large, medium, small), and particle
sizes for VLDL, LDL and HDL. The current IVD test reports LDL-P concen-
trations (nmol/L) from a serum/plasma sample with future goals to re-
port additional lipoprotein parameters such as HDL particle number
(HDL-P). The Vantera Clinical Analyzer is the ﬁrst NMR device cleared
by the FDA for use as a clinical instrument and is now available for dis-
tribution. Itwas developed to address the limiting factors of earlier NMR
instruments by providing: 1) automated sample handling for high-
throughput measurements (b2 min/test), 2) reduced sample volume
requirements (150 μL/test), 3) quick and efﬁcient testing without sam-
ple modiﬁcation or pretreatment and 4) automated calibration and ad-
justment of themagnetic ﬁeld homogeneity, allowing routine operation
by laboratory medical technologists. Additionally, the Vantera footprint
is reasonable for anNMR instrument [10.5(L) × 4(W)× 6(H) feet]mak-
ing it convenient for placement in clinical laboratories. Therefore, de-
ployment of the Vantera Clinical Analyzer should enable broader
adoption of NMR-based applications and expand the number of NMR
tests available in the clinical setting. The aim of this study was to assess
the analytic performance of the LDL-P assay on this FDA approved and
available NMR platform.
Materials and methods
Sample collection and preparation
Serum pools and controls were purchased from Solomon Park
Research Laboratories. Controls were prepared by identifying serum
samples with high and low lipoprotein ranges. Additional serum pools
were prepared in-house from donor subjects identiﬁed at LipoScience
(Raleigh, NC) or Mayo Clinic (Rochester, MN). This study was carried
out in accordance with The Code of Ethics of theWorld Medical Associ-
ation (Declaration of Helsinki), cleared by an Institutional Review Board
and all donors signed consent forms. Samples were drawn into NMR
LipoProﬁle® serum separator tubes (#456293/455232; Greiner Bio-
One) also known as LipoTubes, allowed to clot at room temperature
for 30 min, centrifuged at 3000 rpm for 15 min at room temperature,
and promptly stored at 4 °C. For studies comparing collection tubes,
specimens were drawn into BD Vacutainer serum collection tubes
(red-top, no gel barrier) and allowed to clot as described above or
K2EDTA plasma collection tubes and processed as per themanufacturer
(BD Diagnostics). Specimens (150 μL) for the Vantera were sampled
directly from primary collection tubes or transferred to 13 × 75 mm
tubes, then diluted automatically 1:1with NMRdiluent (50mMsodium
phosphate, 120 mM KCl, 5 mMNa2EDTA, 1 mM CaCl2, pH 7.4) onboard
the Vantera. Sample preparation for NMR Proﬁler analysis included
a 1:1 dilution with NMR diluent using a Tecan EVO autopipetter. On
both platforms, the sample was delivered into the spectrometer's
homogeneous magnetic ﬁeld through a heated transfer line to rapidly
reach the requiredmeasurement temperature. Two levels of serum con-
trolswere included at the beginning and end of each run of test samples.
Acquisition of NMR spectra and data processing
NMR spectra were acquired at the CLIA approved facilities of
LipoScience on the NMR Proﬁler or Vantera Clinical Analyzer, both
equipped with 400 MHz 1H NMR spectrometers (Bruker Bio-Spinand Agilent Technologies, respectively). Data acquisition on the NMR
Proﬁler was performed as described [24] with water suppression
achieved through presaturation.Data acquisition on theVanterawas ac-
complished in a similar fashion with the exception that signal from
water was suppressed using the WET solvent suppression technique
[25]. The NMR data was acquired as 5 blocks of 2 scans on the NMR
Proﬁler and 3 blocks of 4 scans on the Vantera for a total acquisition
time of 40 and 48 s, respectively. For both systems the spectra were
acquired with a sweep width of 4496.4 Hz and 9024 data points. The
data was processed by zeroﬁlling to 32 K points and multiplied by a
Gaussian function to provide resolution enhancement prior to Fourier
Transformation.
Deconvolution of lipoprotein signals
Themethyl signal envelope appearing between 0.718 and 0.914ppm
was analyzed using the LipoProﬁle-3 algorithm,whichmodels the signal
as a combination of lipoprotein and serum protein subcomponent
spectra [22]. The contribution of each subcomponent was determined
by linear least-squares singular value decomposition constrained so
concentrations could not be b0. LDL-P concentrations reported here
are the sum of the IDL and large and small LDL subclass levels and re-
ported in nmol/L units.
Vantera LDL-P trueness controls
To ensure long-term stability and consistency of Vantera LDL-Pmea-
surements, a set of “trueness controls” was developed. Trueness con-
trols consist of a set of three serum control levels, having assigned
LDL-P values determined on multiple Vantera systems and stored
at−80 °C. These are routinely used to benchmark assay performance
and prevent any long term drift of LDL-P values. Assigned values and
uncertainty (±2*SD) for trueness controls were obtained using three
Vanteras, measured for 2 runs per day (5 replicates/run) for three
days. Imprecision for trueness control value assignment was typically
4–5% CV. Accurate recovery of trueness control assigned values was
used to qualify labeling of all subsequent control lots.
Assay performance testing
Sensitivity
Limits of blank (LOB), detection (LOD) and quantitation (LOQ)were
calculated based on Clinical Laboratory Standards Institute (CLSI)
guidelines [26]. To minimize matrix effects for the blank, serum pools
were delipidated by ultracentrifugation (density=1.22 g/mL), the bot-
tom fraction was then removed and dialyzed against phosphate buff-
ered saline (density = 1.006 g/mL). The LOB was determined from 60
measurements obtained from 5 delipidated pools (blank samples) test-
ed 4 times per day for 3 days. LOB was calculated as the mean
+ 1.645*standard deviation (SD) of these measurements. Five serum
pools containing low analyte levels were tested in 4 replicates on 3
days (n=60). LODwas calculated as LOB+ 1.65*pooled SD of the 5 in-
dividual pools. LOQ was estimated as the level of analyte giving impre-
cision better than a total allowable error of 20%. Serum pools containing
low concentrations of LDL-P (9 pools) were tested in replicates of 4 for
3 days.Mean result and coefﬁcient of variation (CV)were calculated for
each pool. A plot of CV versus mean result was generated and ﬁt to a
power function. LOQ was estimated as the intersection of the power
function ﬁt line with CV = 20%.
Imprecision
Within-laboratory imprecision and repeatability were determined
based on CLSI guidelines [27] using serum pools targeted at low, inter-
mediate and high ranges. Testing consisted of duplicate tests run
twice per day for 20 days (n = 80) on one Vantera, while within-run
imprecision was calculated from 20 replicates.
Table 1
Within-laboratory imprecision, repeatability and within-run imprecision for LDL-P
measured on the Vantera Clinical Analyzer.
LDL-P (nmol/L)
Low Intermediate High
Within-laboratorya
Mean 989 1267 1944
SD 52.2 50.1 75.1
CV 5.3% 4.0% 3.9%
Repeatabilitya
Mean 989 1267 1944
SD 48.8 32.6 63.4
CV 4.9% 2.6% 3.3%
Within-runb
Mean 843 1310 1838
SD 48.5 39.1 50.3
CV 5.8% 3.0% 2.7%
a Based on CLSI EP5-A2 tested using 3 controls, 2 runs per day in duplicate for 20 days
(total n = 80).
b Based on 1 run of 20 tests.
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Assay linearity was evaluated based on CLSI guidelines [28] by com-
paring linear regression to higher order polynomial regression for re-
sults from a series of mixtures of high and low serum pools. Serum
pools with elevated LDL-P were obtained by pooling serum specimens
with high levels of lipoproteins and enriched by the addition of LDL iso-
lated by ultracentrifugation [29]. Samples with intermediate LDL-P
were obtained by mixing serum pools with elevated and low levels of
the lipoprotein analytes in varying proportions. Four measurements
were made for each mixture.
Method comparison
Consistent with CLSI guidelines [30], samples were tested in
singlicate on the reference (NMR Proﬁler) and comparator (Vantera
Clinical Analyzer) NMR systems over a period of 8 days of operation
(n = 1526). Concentrations measured covered the expected refer-
ence intervals and beyond. Thirteen samples with a concentration of
LDL-P b300 nmol/L and 23 samples with LDL-P N3500 nmol/L were
excluded. The correlation between the results generated on the two
NMR platforms was evaluated using the Deming regression analysis.
Reference interval
Healthy adult men and women between the ages of 18 and 84 were
recruited by LipoScience or the Mayo Clinic. Subjects were considered
ineligible based on history of heart attack, stroke, renal disease or
heart failure, diabetes, taking lipid-altering drugs, having undergone
procedures for CVD or cancer; body mass index≥30, or blood pressure
reading N140/90 mm Hg. A total of 452 subjects were included. Non-
fasting specimens were drawn into LipoTubes and tested in singlicate
on one Vantera system. Serum samples were also tested for glucose,
creatinine, triglycerides, LDL-C(direct), HDL-C and total cholesterol
on an AU640 (Beckman Coulter Inc.). Cumulative distributions, means,
medians and 95% conﬁdence intervals were calculated. The LDL-P
reference range was estimated using non-parametric analyses with ref-
erence limits at 2.5th and 97.5th percentiles according to the nonpara-
metric method described in CLSI guidelines [31]. Reference intervals
were compared by assessing their median results by a Wilcoxon Rank
Sum test.
Test for interfering substances
A total of 7 endogenous and 23 exogenous substances were tested
for possible assay interference consistent with CLSI guidelines [32].
Stock solutions of substances were prepared in either H2O (20×)
or dimethyl sulfoxide-d6 (DMSO-d6) (80×) depending on solubility.
Substances were individually added to 2 serum pools containing lipo-
protein concentrations at different medical decision levels. Each
serum pool was divided in half; one half was spiked with the 20× or
80× stock solution of each substance and the other half was spiked
with H2O or DMSO-d6 as the control. Testing was performed using
8 replicates for each pool. The results of the test pool spiked with the
substance were compared to the results of the control pool using
a paired difference test [32]. If a statistical difference between test
and control pool results was detected, this difference was checked
to determine whether it was considered to be clinically meaningful
(N10%). Substances for which interference was observed were tested
at multiple concentrations to estimate a threshold at which interfer-
ence exceeded 10%.
Comparison of collection tubes
Blood from 46 donors was drawn into three different tubes:
LipoTube, BD Vacutainer serum tube (red-top, no gel barrier) or
K2EDTA plasma tube. In order to expand the range of measured values,2 specimens with low analyte concentration were diluted (≤50%) and
2 specimens with elevated analyte were spiked with fractionated LDL
(≤10%by volume). A total of 50 specimenswere tested for each analyte.
Results for conventional serum and EDTA plasma tubes were compared
to results for the LipoTube by linear regression.
Stability testing
Three separate studies of 10 donors (n = 30) drawn in LipoTubes
were used to assess LDL-P stability. Samples were stored at 4 °C and
aliquots tested daily. Daily mean results for all donors were evaluated
with acceptable differences falling within ±10% of the day 0 (draw
day) mean.
Results
Assay performance
The NMR LDL-P assaywas assessed for its analytical performance on
the Vantera Clinical Analyzer including the determination of the ability
to reliably detect and quantify LDL particles in serum. The average value
obtained when testing replicate blanks (LOB) was determined to be
0 nmol/L, while the analytical sensitivity or limit of detection (LOD)
was calculated to be 41 nmol/L. Testing of nine serum pools, with
LDL-P concentrations ranging from 85 to 261 nmol/L, gave a functional
sensitivity or limit of quantitation (LOQ) of 132 nmol/L with a CV
of b10%. Controls with three levels of lipoprotein analytes (low, inter-
mediate and high) were tested for inter-assay (within-lab) precision,
intra-assay (within-run) precision and repeatability. The CVs ranged
from 3.9 to 5.3% for within-lab precision, 2.6–4.9% for repeatability
and 2.7–5.8% forwithin-run precision (Table 1). In order to test the abil-
ity of the LDL-P assay to detect LDL particles, the measured values were
plotted against the actual or expected concentrations. The measured
LDL-P values demonstrated a linear relationship with the expected
values within the range of 225–4320 nmol/L with a correlation coefﬁ-
cient of R2 = 0.99 (Fig. 1A).
Method comparison
In order to ensure that the performance of the LDL-P assay on the
Vantera Clinical Analyzer was similar to the well characterized LDL-P
assay on the NMR Proﬁler, a method comparison was performed.
Specimens outside the reportable range of 300–3500 nmol/L were
excluded from the analysis leaving the total number of specimens ana-
lyzed to 1490. The linear regression (data not shown) for the LDL-P data,
Fig. 1. A) Results of linearity testing for the Vantera LDL-P assay. B) Comparison of Vantera and NMR Proﬁler methods for detection and quantiﬁcation of LDL-P. C) Residual plot of LDL-P
assays.
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intercept of −36.6 and correlation coefﬁcient (R2) of 0.96 and the
Deming regression (Fig. 1B) gave a slope of 1.05, intercept of −83.4
and R2 value of 0.96. The residuals, differences between the LDL-P
values and the regression line, were plotted against the estimated con-
centration for LDL-P. The points on the plot were randomly dispersed
around the horizontal axis, suggesting that the results of the two assays
were linearly related, and there appeared to be only one signiﬁcant
outlier (Fig. 1C).
Reference interval determination
A population of healthy individuals (n = 452) was used to deter-
mine the reference interval for the LDL-P assay. Fig. 2 shows the distri-
bution of LDL-P values in this population. The mean LDL-P value was
1193 ± 472 nmol/L and the median was 1127 nmol/L, which deﬁned
the 95 percentile range for reference interval as 457–2282 nmol/L
(Fig. 2). The reference interval for LDL-P showed signiﬁcant differences
between genders (men = 372–2365; women = 480–2057 nmol/L)
as did the mean (men = 1279 ± 491; women = 1148 ± 456 nmol/L)
(p = 0.002). For comparison, the LDL-C results from the same refer-
ence population were juxtaposed to the LDL-P results (Fig. 2). The
mean LDL-C was 113 ± 34 mg/dL. According to the National Choles-
terol Education Panel's Adult Treatment Panel (ATP) III guidelines
[33], LDL-C levels below 100 mg/dL (b20th percentile based on the
Framingham Offspring Study and NHANES III Survey) are considered“optimal” for patients who are at high risk for CVD. In this reference
population, we found that an LDL-C value of roughly 100 mg/dL
(40th percentile) corresponded to an LDL-P value of approximately
1000 nmol/L (Fig. 2).
Interfering substances
Thirty substances were tested for their potential to interfere with
the LDL-P assay. Results (Table 2) showed that interference was not
detectable or b10% at the highest level tested for 24 of 30 substances
tested. Six substances showed potential interference with the LDL-P
assay in the initial screening andwere tested atmultiple concentrations
to identify levels at which interference was signiﬁcant. Four substances
(albumin, fenoﬁbrate, ibuprofen and naproxen) were considered to be
low risk for eliciting analytical interference. Albumin suppressed mea-
sured LDL-P at the upper limit of the tested range,with 10% interference
estimated to occur at 59 mg/mLexogenous albumin. The recommended
test ranges for albumin, based on CLSI guidelines, are 35–50 mg/mL
[32]. Fenoﬁbrate elicited an apparent increase in measured LDL-P
at concentrations N52 μM, which is above the expected therapeutic
concentration (41.6 μM) [32]. Similarly, ibuprofen andnaproxen elicited
an apparent increase in measured LDL-P at concentrations N1228
and 2170 μM, well above therapeutic concentrations of 48.5–340
and 130–521 μM, respectively [32]. The remaining two substances
presented a greater risk for interference because the concentration at
which interference occurred was within the therapeutic range. Salicylic
Fig. 2. Distribution of LDL-P values from 452 reference range study participants (top).
Means, medians, and reference intervals for LDL-P and LDL-C for all participants in the
reference range study as well as for just the men and women from the same population
(bottom).
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LDL-P values (therapeutic range of 0.7–2.8 mM or 500–1500 mg) [32].
Clopidogrel hydrogen sulfate at concentrations N40 μg/mL (201 mg)
resulted in an approximate 10–20% increase in LDL-P (therapeutic
range≤120 μg/mL or≤600mg). As per CLSI standards for interference
testing, clopidogrel hydrogen sulfate concentrations tested are repre-
sentative of parent drug concentrations and are not reﬂective of active
metabolite, therapeutic concentrations.
Comparison of collection tubes
Various tube types were tested for their compatibility with the NMR
LDL-P assay. The results performed on specimens collected in LipoTubes
were plotted against those obtained in conventional red-top serum
tubes (no gel barrier) (Fig. 3A). A linear regression analysis was per-
formed and the resulting line gave a slope of 0.97 (R2 = 0.96). More-
over, BD red-top, no gel serum tubes showed no signiﬁcant bias based
on either 95% conﬁdence intervals around the correlation slope and in-
tercept, or estimation of bias from Bland–Altman residual plots (data
not shown). For the LDL-P assay performed on specimens collected in
EDTA plasma tubes (Fig. 3B) the resulting linear regression produced a
slope of 0.94 (R2 = 0.97). The LDL-P assay results in EDTA plasma
tubes, however, were modestly (3–7%) lower than results from speci-
mens collected in LipoTubes.Stability
Thirty serum samples were evaluated for reproducibility in quantiﬁ-
cation over time with acceptable measurements falling within ±10% of
the day 0mean. Results showed that themean LDL-P valueswere stable
out to day 6 with changes of b10% (Table 3). However, on day 7 a
change of 10.2% was observed.
Discussion
Because of commonly encountered variability in the amount of
cholesterol carried in LDL particles, either for physiologic reasons (e.g.
metabolic syndrome or type 2 diabetes) or as a result of statin therapy,
LDL-C is frequently discordant with LDL-P [4,34,35]. When discordance
is present, LDL-P is a stronger predictor of coronary heart disease risk, as
well as on-trial LDL-related risk among patients treated with lipid-
altering therapy. As a result, several expert panels recommend the use
of LDL-P as a target of therapy to guide management and adjudicate
response to pharmacotherapy in patients with increased CVD risk
[19–21]. The NMR LipoProﬁle® test, which reports LDL-P values, was
cleared by the FDA for use on the Vantera Clinical Analyzer.
The ability to reliably quantify lipoprotein particle concentrations
of clinical serum/plasma specimens via NMR has been established for
several years using highly specialized equipment and trained operators
[22,24,36]. In the past, this technology has not been amenable to testing
outside a central laboratory facility, in part because of the lack of
an NMR platform that was compatible with typical clinical laboratory
operations. The Vantera Clinical Analyzer includes a number of features
to address this gap: 1) an operator interface developed speciﬁcally
for the clinical setting, 2) simpliﬁed set-up, calibration, maintenance
and operation 3) high-throughput, fully-automated sample processing
(N35 samples/h) and 4) a smaller footprint. Results from this study
demonstrate the successful development of an automated NMR-based
assay for LDL-P that showed the precision, sensitivity, measurement
range and linearity suitable for routine clinical measurements. The
types of tubes for sample collection and stability further support and
reconﬁrm previously described observations [22]. Furthermore, the ref-
erence range veriﬁcation study provides a framework for understanding
the relationship between particle-based and cholesterol-based lipopro-
tein measurements. Lastly, a previously published comparison of NMR-
measured LDL-P values with LDL apoB (after removing VLDL by ultra-
centrifugation) revealed a strong correlation between the twomeasures
of LDL particle concentration (r = 0.93) [22], suggesting that NMR-
measured LDL-P may be a simple, inexpensive means of assessing the
number of atherogenic LDL particles without the results being con-
founded by the inclusion of VLDL particles.
Because NMR technology supports the simultaneous determination
of multiple analytes across the NMR spectrum, it provides an attractive
tool for proﬁling a range of biological molecules and metabolites and
has widespread applications related to personalized diagnostics. NMR
has been applied in the research setting to identify serum/plasma
markers of prediabetes/diabetes, cancer, inﬂammation, Alzheimer's
disease and CVD [37–39]. The ability to test complex clinical specimens
requires that interference from drugs and other substances is not a
critical issue. NMR technology is immune from the type of interferences
common to chemical methods (e.g. turbidity). Since all the NMR-based
lipoprotein information are extracted from the terminal methyl lipid
signals, only substances that contain a methyl signal that appear in the
lipid region of 0.7–0.9 ppm can potentially cause interference with the
lipoprotein analysis. Dramatic changes in the matrix including ionic
strength and pH can have an effect on the chemical shift of the lipid sig-
nal, though this is unlikely to occur with samples collected following
standard specimen requirements. However, the in vitro method,
which is recommended by CLSI for determining common interfering
substances, may cause the types of artiﬁcial changes to the spectra
that are unlikely to occur after drug administration in vivo. Additionally,
Table 2
Summary of interference testing for the NMR LDL-P assay measured on the Vantera Clinical Analyzer.
Substance Drug name Test concentration Concentration eliciting interference
Bilirubin, unconj. – 200 μg/mL (342 μM) –
Bilirubin, conj. – 289 μg/mL (342 μM) –
Creatinine – 50 μg/mL (442 μM) –
Hemoglobin – 2 mg/mL –
Protein-albumina – 0–60 mg/mL Interfered N 59 mg/mL
Urea – 2.6 mg/mL (43 mM) –
Uric acid – 235 μg/mL (1.4 mM) –
Acetaminophen Tylenol 200 μg/mL (1.3 mM) –
Acetylsalicylic acid Aspirin 0–660 μg/mL (3.6 mM) –
Atorvastatin Lipitor 52 μg/mL –
Clopidogrel hydrogen sulfate Plavix 0–360 μg/mL Interfered N 40 μg/mL
Enalaprilat dihydrate Vasotec 0.3 μg/mL (0.9 μM) –
Fenoﬁbrate Tricor 0–45 μg/mL (125 μM) Interfered N 19 μg/mL (52 μM)
Furosemide Lasix 60 μg/mL (181 μM) –
Glipizide Glucotrol 2.0 μg/mL (4.5 μM) –
Heparin Lovenox 3000 U/L –
Hydralazine hydrochloride Apresoline 180 μg/mL –
Ibuprofen sodium salt Advil 0–560 μg/mL (2425 μM) Interfered N 280 μg/mL (1228 μM)
Isosorbide dinitrate Isordil 150 ng/mL (636 nM) –
Menhaden oil Fish oil 2.4 mg/mL –
Metformin hydrochloride Glucophage 600 μg/mL –
Metoprolol tartrate Lopressor 13 μg/mL (18.7 μM) –
Naproxen sodium Aleve 0–550 μg/mL (2170 μM) Interfered N 550 μg/mL (2170 μM)
Nicotinic acid sodium salt Vitamin B3 0–1.2 mg/mL –
Nifedipine Adalat 0.4 μg/mL (1.2 μM) –
Pioglitazone hydrochloride Actos 27 μg/mL –
Piroxicam Feldene 60 μg/mL (181 μM) –
Pravastatin Pravachol 48 μg/mL –
Salicylic acid – 0–599 μg/mL (4.3 mM) Interfered N 185 μg/mL (1.3 mM)
Simvastatin Zocor 48 μg/mL –
Test concentrations were obtained from EP7-A2, Appendix C, where available.
a Test concentration range reﬂects added albumin (does not include endogenous albumin).
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form (30–60 min) after administration [40]. The clopidogrel metabo-
lites do not contain methyl groups that would arise within the lipid
region of the NMR spectrum nor are they hydrophobic enough to bind
to the lipoprotein particles and affect their structures. Therefore, they
are unlikely to interfere with lipoprotein particle quantitation. Unfortu-
nately, the clopidogrel metabolites were not available for testing at the
time this study was conducted. Furthermore, the therapeutic range for
clopidogrel was calculated using 600 mg as the worst case scenario.
The FDA approved loading dose, suggested for treatment of patientsFig. 3. Comparison of collection tubes for LDL-P. A) LDL-P results for BD Vacutainer serum tubes
tubes compared to the LipoTube (gel barrier).with unstable angina and non-STEMI, is 300 mg and the routine daily
dose is 75mg. Given that themajority of the drug is rapidlymetabolized
to its active form and lower daily maintenance dose, the≥201 mg con-
centration of the inactive parent compound is not likely to be present
in specimens collected from patients routinely taking clopidogrel.
Similarly, the recommended daily doses of aspirin are 81–160 mg for
CVD and 325–650 mg for various other indications. The results of this
study revealed that a patient would have to achieve a circulating con-
centration of salicylic acid, the active form of aspirin, ≥929 mg in
order to elicit an effect on the LDL-P results. The reported therapeutic(no gel barrier) compared to the LipoTube (gel barrier). B) LDL-P results for EDTA plasma
Table 3
Stability of LDL-P measured by NMR assay on the Vantera Clinical Analyzer.
Day N Mean LDL-P (nmol/L) %bias
0 30 1210 n/a
1 30 1210 0.0
2a 20 1201 2.2
3a 20 1234 5.0
4 30 1314 8.6
5 30 1295 7.0
6 30 1323 9.3
7b 29 1337 10.2
a Days 2 & 3 not observed in 1 of 3 studies (n = 20). %bias calculated relative to mean
day 0 LDL-P of 1175 nmol/L.
b Day 7missing 1 subject due to short draw (n = 29). %bias calculated relative tomean
day 0 LDL-P of 1213 nmol/L.
209S.P. Matyus et al. / Clinical Biochemistry 47 (2014) 203–210range for salicylic acid encompasses topical acne treatment. Therefore,
patients are not likely to experience circulating salicylic acid concentra-
tions ≥929 mg with routine, daily aspirin or topical salicylic acid treat-
ment. In conclusion, although in vitro testing in this study indicated
some sources of potential interference, this does not prohibit reliable
LDL-P quantitation since most interferences were observed at concen-
trations above the therapeutic window or were not likely to affect
NMR spectra obtained from patients taking normal therapeutic doses
of these substances.
The successful development of amethod tomeasure LDL-P on a fully
automated platform allows NMR technology dissemination into the
routine, clinical laboratory setting and creates the opportunity for
NMR-based testing across a broader range of clinical applications. In
fact, several leading national reference laboratories and large hospital
system laboratories have successfully integrated the Vantera into their
clinical lab operations. Current efforts are focused on expanding the
menu of NMR-based tests that are available for physicians to make in-
formed decisions on patient care, especially in an erawhen personalized
medicine, using tests that are inexpensive and widely available, is be-
coming highly desirable.
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